ReviewJournal of the Endocrine Society2021
Intersection of Polycystic Ovary Syndrome and the Gut Microbiome.
Review in Journal of the Endocrine Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 96 citations in OpenAlex.
- Effect of Probiotic Supplementation on Reproductive Outcomes of Women With Polycystic Ovary Syndrome Who Are Candidates for Intrauterine Insemination: A Randomized, Double-Blind, Placebo-Controlled Trial.Endocrinology, diabetes & metabolism · 2026Trial
- Efficacy of multi-strain probiotic along with dietary and lifestyle modifications on polycystic ovary syndrome: a randomised, double-blind placebo-controlled study.European journal of nutrition · 2022Trial
- The cervicovaginal gut microbiota axis as a key determinant of systemic physiology.Gut microbes · 2026Review
- Polyendocrine Metabolic Ovarian Syndrome (PMOS; Formerly Polycystic Ovary Syndrome/PCOS) and Susceptibility to Microbial Infections: Mechanisms, Clinical Management, and Reproductive Consequences - A Comprehensive Review.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Exploring emerging concepts in the pathophysiology of PCOS: microbiome dysbiosis and immunological dysregulation.Reproduction & fertility · 2026Review
- Avena sativa-derived avenanthramides suppress 12-lipoxygenase activity and downstream arachidonic acid metabolites in letrozole-induced PCOS rats.Scientific reports · 2026Article
- Probiotic Modulation of the Gut-Ovary and Gut-Myometrium Axes: An In Vitro Study.Microorganisms · 2026Article
- Unraveling the mechanisms of PCOS: the interplay between gut microbiota and the immune system.Journal of ovarian research · 2026Review
- Microbial Dysbiosis and Pathogenic Interplay in the Gut-Vaginal Axis: Implications for Polycystic Ovary Syndrome: A Critical Review.Current microbiology · 2026Review
- Butyric acid-based self-assembling nanoparticles: a potential strategy to prevent development of polycystic ovary syndrome.Molecular human reproduction · 2026Article
- Ketogenic diet combined with probiotics for polyendocrine metabolic ovarian syndrome: research progress from the perspective of the gut microbiota-host metabolic axis.Frontiers in nutrition · 2026Review
- The gut microbiota-metabolite axis in polycystic ovary syndrome: differential characteristics between infertile and conceived populations.Frontiers in microbiology · 2026Article
- The gut microbiome in polycystic ovary syndrome: mechanistic pathways and therapeutic potential of microbiota-targeted interventions.Frontiers in endocrinology · 2026Review
- The impact of gut microbiota on insulin resistance in polycystic ovary syndrome: mechanisms and therapeutic prospects.Frontiers in cellular and infection microbiology · 2026Review
- New Challenges and Perspectives in Polycystic Ovary Syndrome.Journal of clinical medicine · 2025Article
- Molecular Impact of Metabolic and Endocrine Disturbance on Endometrial Function in Polycystic Ovary Syndrome.International journal of molecular sciences · 2025Review
- The Role of Nutraceuticals and Probiotics in Addition to Lifestyle Intervention in the Management of Childhood Obesity-Part 2: Comorbidities.Nutrients · 2025Review
- Optimization of Growth Conditions of Streptomyces coelicoflavus Strain AUMC B- 535 in Rock Phosphate Beneficiation Process.Current microbiology · 2025Article
- Influence of menstrual cycle and oral contraception on taxonomic composition and gas production in the gut microbiome.Journal of medical microbiology · 2025Article
- Microbial Guardians or Foes? Metagenomics Reveal Association of Gut Microbiota in Intestinal Toxicity Caused by DON in Mice.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The etiology of polycystic ovary syndrome (PCOS) remains unclear, although studies indicate that both genetic and environmental factors contribute to the syndrome. In 2012, Tremellen and Pearce proposed the idea that dysbiosis of the intestinal (gut) microbiome is a causative factor of metabolic and reproductive manifestations of PCOS. In the past 5 years, studies in both humans and rodent models have demonstrated that changes in the taxonomic composition of gut bacteria are associated with PCOS. Studies have also clearly shown that these changes in gut microbiota are associated with PCOS as opposed to obesity, since these changes are observed in women with PCOS that are both of a normal weight or obese, as well as in adolescent girls with PCOS and obesity compared with body mass index- and age-matched females without the disorder. Additionally, studies in both women with PCOS and rodent models of PCOS demonstrated that hyperandrogenism is associated with gut microbial dysbiosis, indicating that androgens may modulate the gut microbial community in females. One study reported that the fecal microbiome transplantation of stool from women with PCOS or exposure to certain bacteria resulted in a PCOS-like phenotype in mice, while other studies showed that exposure to a healthy gut microbiome, pre/probiotics, or specific gut metabolites resulted in protection from developing PCOS-like traits in mice. Altogether, these results suggest that dysbiosis of the gut microbiome may be sufficient to develop PCOS-like symptoms and that modulation of the gut microbiome may be a potential therapeutic target for PCOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.